Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis

Annals of Neurology

Volumn 75, Issue 1, 2014, Pages 43-49

  Sormani, Maria Pia ^a   Arnold, Douglas L ^b   De Stefano, Nicola ^c  

^a UNIVERSITY OF GENOA   (Italy)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPHY; BRAIN; DISABLED PERSONS; DISEASE PROGRESSION; HUMANS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84894038191     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24018     Document Type: Article

References (28)

1. Sormani MP, Bonzano L, Roccatagliata L, et al. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 2009; 65: 268-275.
2. Sormani MP, Bruzzi P,. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomized trials. Lancet Neurol 2013; 12: 669-676.
3. Sormani MP, Stubinski B, Cornelisse P, et al. Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis. Mult Scler 2011; 17: 541-549.
4. Sormani MP, Bruzzi P, Comi G, Filippi M,. MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients. Neurology 2002; 58: 417-421.
5. Sormani MP, Bruzzi P, Beckmann K, et al. MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN beta-1b. Neurology 2003; 60: 1462-1466.
6. Sormani MP, Bonzano L, Roccatagliata L, et al. Surrogate endpoints for EDSS worsening in multiple sclerosis: a meta-analytic approach. Neurology 2010; 75: 302-309.
7. Barkhof F, Calabresi P, Miller DH, Reingold SC,. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 2009; 5: 256-266.
8. Zivadinov R, Reder AT, Filippi M, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 2008; 71: 136-144.
9. Tedeschi G, Lavorgna L, Russo P, et al. Brain atrophy and lesion load in a large population of patients with multiple sclerosis. Neurology 2005; 65: 280-285.
10. Amato MP, Portaccio E, Goretti B, et al. Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. Arch Neurol 2007; 64: 1157-1161.
11. De Stefano N, Giorgio A, Battaglini M, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 2010; 74: 1868-1876.
12. Smith SM, De Stefano N, Jenkinson M, Matthews PM,. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 2001; 25: 466-475.
13. Rudick RA, Fisher E, Lee JC, et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999; 53: 1698-1704.
14. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
15. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-923.
16. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel,open-label trial. Lancet Neurol 2008; 7: 903-914.
17. O'Connor P, Filippi M, Arnason B, et al. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009; 8: 889-897.
18. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.
19. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010; 362: 416-426.
20. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365: 1293-1303.
21. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367: 1098-1107.
22. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367: 1087-1097.
23. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012; 380: 1819-1828.
24. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012; 380: 1829-1839.
25. Calabresi PA, Radue EW, Goodin D, et al. Efficacy and safety of fingolimod in patients with relapsing remitting multiple sclerosis (RRMS): results from an additional 24-month double-blind, placebo-controlled study (FREEDOMS II study). Poster presented at: 64th AAN Annual Meeting; April 21-28, 2012; New Orleans, Lousiana. Poster P01.015, P015 AAN 2012.
26. Duning T, Kloska S, Steinsträter O, et al. Dehydration confounds the assessment of brain atrophy. Neurology 2005; 64: 548-550.
27. Prentice RL,. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8: 431-440.
28. Sormani MP, Miller DH, Comi G, et al. Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets. J Neurol Neurosurg Psychiatry 2001; 70: 494-499.